TY  - JOUR

T1  - Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

JO  - Journal of Thoracic Oncology

UR  - http://eprints.whiterose.ac.uk/110808/

PY  - 2014/11/01

AU  - Natale R

AU  - Blackhall F

AU  - Kowalski D

AU  - Ramlau R

AU  - Bepler G

AU  - Grossi F

AU  - Lerchenmüller C

AU  - Pinder-Schenck M

AU  - Mezger J

AU  - Danson S

AU  - Gadgeel SM et al

ED  - 

DO  - DOI: 10.1097/JTO.0000000000000285

VL  - 9

IS  - 11

SP  - 1704

EP  - 1708

Y2  - 2024/09/19

ER  -